Efficacy and Safety of Crizotinib in Advanced or Recurrent 
ALK-positive Non-small Cell Lung Cancer

Conclusion Crizotinib can be used for the treatment of advanced NSCLC with ALK fusion/translocation. It is highly effective and well tolerated. 
 DOI: 10.3779/j.issn.1009-3419.2019.08.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research